Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.

Michael GuentherMichael HaasVolker HeinemannStephan KrugerChristoph Benedikt WestphalenMichael von Bergwelt-BaildonJulia MayerleJens WernerThomas KirchnerStefan BoeckSteffen Ormanns

Published in: British journal of cancer (2020)

The Clinical trial registry identifier is NCT00440167.

Keyphrases

clinical trial
open label
double blind
phase ii
inflammatory response
toll like receptor
lps induced
study protocol
phase iii
locally advanced
placebo controlled
squamous cell carcinoma
randomized controlled trial
rectal cancer
immune response